PDF herunterladen
Semin Thromb Hemost 2013; 39(08): 973
DOI: 10.1055/s-0033-1358798
Erratum
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Pathogen Safety of Long-Term Treatments for Bleeding Disorders: (Un)Predictable Risks and Evolving Threats

Autor*innen

  • Giovanni Di Minno

    1   Department of Clinical Medicine and Surgery, Regional Reference Centre for Coagulation Disorders, Napoli, Italy

  • Mariana Canaro

    2   Department of Hemostasis and Thrombosis, Son Espases Universitary Hospital, Palma de Mallorca, Spain

  • James W. Ironside

    3   National Creutzfeldt-Jakob Disease Surveillance Unit, School of Molecular and Clinical Medicine, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom

  • David Navarro

    4   Department of Microbiology, Microbiology Service, Hospital Clínico Universitario, School of Medicine, University of Valencia, Valencia, Spain

  • Carlo F. Perno

    5   Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy

  • Andreas Tiede

    6   Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

  • Lutz Guertler

    7   Max von Pettenkofer Institute for Hygiene and Medical Microbiology, University of München, Munich, Germany
Weitere Informationen

Address for correspondence

Giovanni Di Minno, MD, PharmD
Dipartimento di Medicina Clinica e Chirurgia, Regional Reference Centre for Coagulation Disorders
Federico II University, Via S. Pansini 5, 80131 Naples
Italy   

Publikationsverlauf

Publikationsdatum:
20. Oktober 2013 (online)

 
 als PDF herunterladen Lizenzen und Reprints

Originalartikel zu diesem Erratum:

Pathogen Safety of Long-Term Treatments for Bleeding Disorders: (Un)Predictable Risks and Evolving ThreatsSemin Thromb Hemost 2013; 39(07): 779-793
DOI: 10.1055/s-0033-1354420

The authors regret mentioning potential misinformation for few products in Tables 2 and 3 of the above article (Volume 39, Number 7, pp. 782–786). The complete details and updates are summarized below:

Page No.

Column head

Row

Potential misinformation

Corrected information

Table 2

783

Potential risks

Kogenate FS (Bayer)

Allergic type hypersensitivity reactions; risk of infection from unknown/emerging viral/other pathogens; risk of thrombotic events; formation of neutralizing antibodies; thrombophlebitis/thrombosis at infusion/catheter site

Allergic type hypersensitivity reactions; risk of thrombotic events; formation of neutralizing antibodies; thrombophlebitis/thrombosis at infusion/catheter site

784

Potential risks

Xyntha/ReFacto AF (Pfizer)

Allergic type hypersensitivity reactions; risk of infection from unknown/emerging viral/other pathogens; formation of neutralizing antibodies; lack of effect (bleeding events)

Allergic type hypersensitivity reactions; formation of neutralizing antibodies; lack of effect (bleeding events)

Table 3

786

Purification

BeneFIX (Pfizer)

Immunoaffinity chromatography

Affinity chromatography

Address for correspondence

Giovanni Di Minno, MD, PharmD
Dipartimento di Medicina Clinica e Chirurgia, Regional Reference Centre for Coagulation Disorders
Federico II University, Via S. Pansini 5, 80131 Naples
Italy   

  Lizenzen und Reprints